- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.02. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 12.02.2025 | 617 | Xetra Newsboard | The following instruments on XETRA do have their first trading 12.02.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 12.02.2025
Aktien
1 JP3556000002 Toa Corp.
2 CNE100006NX7... ► Artikel lesen | |
| COEGIN PHARMA Aktie jetzt für 0€ handeln | |||||
| 06.01. | XFRA DELETION OF INSTRUMENTS FROM XETRA - 06.01.2025 | 545 | Xetra Newsboard | The following instruments on XETRA do have their last trading day on 06.01.2025Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 06.01.2025ISIN NameSE0020357754 COEGIN PHARMA ABDE000DJ9AB57... ► Artikel lesen | |
| 25.11.24 | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 25.11.2024 | 1.897 | Xetra Newsboard | The following instruments on XETRA do have their first trading 25.11.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 25.11.2024
Aktien
1 ID1000113707 PT Bank Tabungan Negara... ► Artikel lesen |
3 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,122 | -13,60 % | EQS-News: Evotec SE: Bekanntgabe der Ergebnisse für die ersten neun Monate 2025 am 05. November 2025 | EQS-News: Evotec SE
/ Schlagwort(e): 9-Monatszahlen
Evotec SE: Bekanntgabe der Ergebnisse für die ersten neun Monate 2025 am 05. November 2025
29.10.2025 / 09:45 CET/CEST
Für... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 71,50 | 0,00 % | Tarsus outlines $140M-$145M Q4 sales target while expanding XDEMVY adoption and pipeline progress | ||
| HARMONY BIOSCIENCES | 30,720 | 0,00 % | Harmony Biosciences raises 2025 revenue outlook to $845M-$865M amid record WAKIX patient growth and advancing pipeline | ||
| AVIDITY BIOSCIENCES | 69,83 | 0,00 % | Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think) | ||
| QIAGEN | 38,275 | -3,53 % | Märkte am Morgen: AMD, Uber, Super Micro Computer, Amgen, Qiagen | Nach dem starken Monatsauftakt hat der DAX spürbar an Schwung verloren. Der Leitindex fiel am Dienstag zeitweise um zwei Prozent, konnte sich aber leicht erholen und schloss 0,76 Prozent tiefer bei... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 17,325 | 0,00 % | Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | BOULDER, Colo., Nov. 3, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,000 | 0,00 % | Recursion names Najat Khan CEO, succeeding co-founder Chris Gibson; stock down | ||
| PRAXIS PRECISION MEDICINES | 171,86 | 0,00 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| UPSTREAM BIO | 25,040 | 0,00 % | Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress | ||
| COGENT BIOSCIENCES | 14,140 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results | Phase 3 PEAK results in 2nd-line GIST patients expected in November; pivotal APEX results in AdvSM patients expected in December Breakthrough Therapy Designation granted for bezuclastinib; New Drug... ► Artikel lesen | |
| PRIME MEDICINE | 4,300 | 0,00 % | Prime Medicine, Inc.: Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer | CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies... ► Artikel lesen | |
| ADMA BIOLOGICS | 14,620 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,495 | 0,00 % | Summit Therapeutics to Present at Upcoming Investor Conferences | Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this... ► Artikel lesen | |
| BEAM THERAPEUTICS | 22,710 | 0,00 % | Beam Therapeutics GAAP EPS of -$1.10 misses by $0.09, revenue of $9.69M misses by $3.03M | ||
| DYNE THERAPEUTICS | 21,505 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug.... ► Artikel lesen |
COEGIN PHARMA AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +3,97 % bei einem Aktienkurs von 0,576 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu COEGIN PHARMA AB finden Sie auf Wallstreet Online.